216 related articles for article (PubMed ID: 28334751)
21. Dysregulated iron metabolism in C. elegans catp-6/ATP13A2 mutant impairs mitochondrial function.
Anand N; Holcom A; Broussalian M; Schmidt M; Chinta SJ; Lithgow GJ; Andersen JK; Chamoli M
Neurobiol Dis; 2020 Jun; 139():104786. PubMed ID: 32032734
[TBL] [Abstract][Full Text] [Related]
22. Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atp13a2-Deficient Mice.
Sato S; Koike M; Funayama M; Ezaki J; Fukuda T; Ueno T; Uchiyama Y; Hattori N
Am J Pathol; 2016 Dec; 186(12):3074-3082. PubMed ID: 27770614
[TBL] [Abstract][Full Text] [Related]
23. The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms.
Park JS; Blair NF; Sue CM
Mov Disord; 2015 May; 30(6):770-9. PubMed ID: 25900096
[TBL] [Abstract][Full Text] [Related]
24. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity.
Ramonet D; Podhajska A; Stafa K; Sonnay S; Trancikova A; Tsika E; Pletnikova O; Troncoso JC; Glauser L; Moore DJ
Hum Mol Genet; 2012 Apr; 21(8):1725-43. PubMed ID: 22186024
[TBL] [Abstract][Full Text] [Related]
25. Loss of ATP13A2 impairs glycolytic function in Kufor-Rakeb syndrome patient-derived cell models.
Park JS; Koentjoro B; Davis RL; Sue CM
Parkinsonism Relat Disord; 2016 Jun; 27():67-73. PubMed ID: 27039055
[TBL] [Abstract][Full Text] [Related]
26. Novel mutations in ATP13A2 associated with mixed neurological presentations and iron toxicity due to nonsense-mediated decay.
Kırımtay K; Temizci B; Gültekin M; Yapıcı Z; Karabay A
Brain Res; 2021 Jan; 1750():147167. PubMed ID: 33091395
[TBL] [Abstract][Full Text] [Related]
27. Regulation of ATP13A2 via PHD2-HIF1α Signaling Is Critical for Cellular Iron Homeostasis: Implications for Parkinson's Disease.
Rajagopalan S; Rane A; Chinta SJ; Andersen JK
J Neurosci; 2016 Jan; 36(4):1086-95. PubMed ID: 26818499
[TBL] [Abstract][Full Text] [Related]
28. Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction.
Park JS; Koentjoro B; Veivers D; Mackay-Sim A; Sue CM
Hum Mol Genet; 2014 Jun; 23(11):2802-15. PubMed ID: 24399444
[TBL] [Abstract][Full Text] [Related]
29. Protection against Mitochondrial and Metal Toxicity Depends on Functional Lipid Binding Sites in ATP13A2.
Martin S; van Veen S; Holemans T; Demirsoy S; van den Haute C; Baekelandt V; Agostinis P; Eggermont J; Vangheluwe P
Parkinsons Dis; 2016; 2016():9531917. PubMed ID: 27073711
[TBL] [Abstract][Full Text] [Related]
30. Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants.
Covy JP; Waxman EA; Giasson BI
J Neurosci Res; 2012 Dec; 90(12):2306-16. PubMed ID: 22847264
[TBL] [Abstract][Full Text] [Related]
31. ATP13A2 deficiency disrupts lysosomal polyamine export.
van Veen S; Martin S; Van den Haute C; Benoy V; Lyons J; Vanhoutte R; Kahler JP; Decuypere JP; Gelders G; Lambie E; Zielich J; Swinnen JV; Annaert W; Agostinis P; Ghesquière B; Verhelst S; Baekelandt V; Eggermont J; Vangheluwe P
Nature; 2020 Feb; 578(7795):419-424. PubMed ID: 31996848
[TBL] [Abstract][Full Text] [Related]
32. Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review.
Yang X; Xu Y
Biomed Res Int; 2014; 2014():371256. PubMed ID: 25197640
[TBL] [Abstract][Full Text] [Related]
33. ATP13A2 facilitates HDAC6 recruitment to lysosome to promote autophagosome-lysosome fusion.
Wang R; Tan J; Chen T; Han H; Tian R; Tan Y; Wu Y; Cui J; Chen F; Li J; Lv L; Guan X; Shang S; Lu J; Zhang Z
J Cell Biol; 2019 Jan; 218(1):267-284. PubMed ID: 30538141
[TBL] [Abstract][Full Text] [Related]
34. Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation.
Inzelberg R; Estrada-Cuzcano A; Laitman Y; De Vriendt E; Friedman E; Jordanova A
J Parkinsons Dis; 2018; 8(3):399-403. PubMed ID: 29966207
[TBL] [Abstract][Full Text] [Related]
35. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9).
Eiberg H; Hansen L; Korbo L; Nielsen IM; Svenstrup K; Bech S; Pinborg LH; Friberg L; Hjermind LE; Olsen OR; Nielsen JE
Clin Genet; 2012 Sep; 82(3):256-63. PubMed ID: 21696388
[TBL] [Abstract][Full Text] [Related]
36. Parkinson's disease-associated human P5B-ATPase ATP13A2 increases spermidine uptake.
De La Hera DP; Corradi GR; Adamo HP; De Tezanos Pinto F
Biochem J; 2013 Feb; 450(1):47-53. PubMed ID: 23205587
[TBL] [Abstract][Full Text] [Related]
37. ATP13A2 modifies mitochondrial localization of overexpressed TOM20 to autolysosomal pathway.
Hatori Y; Kanda Y; Nonaka S; Nakanishi H; Kitazawa T
PLoS One; 2022; 17(11):e0276823. PubMed ID: 36445873
[TBL] [Abstract][Full Text] [Related]
38. Lysosomal dysfunction in neurodegeneration: the role of ATP13A2/PARK9.
Usenovic M; Krainc D
Autophagy; 2012 Jun; 8(6):987-8. PubMed ID: 22561922
[TBL] [Abstract][Full Text] [Related]
39. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome.
Grünewald A; Arns B; Seibler P; Rakovic A; Münchau A; Ramirez A; Sue CM; Klein C
Neurobiol Aging; 2012 Aug; 33(8):1843.e1-7. PubMed ID: 22296644
[TBL] [Abstract][Full Text] [Related]
40. ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons.
Matsui H; Sato F; Sato S; Koike M; Taruno Y; Saiki S; Funayama M; Ito H; Taniguchi Y; Uemura N; Toyoda A; Sakaki Y; Takeda S; Uchiyama Y; Hattori N; Takahashi R
FEBS Lett; 2013 May; 587(9):1316-25. PubMed ID: 23499937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
